Regeneron Pharmaceuticals

REGN · Moat type: REGULIERUNG

MoatScore

8/10

Fair Value

1,158 USD

Margin of Safety

+41.4 %

Rating

STARK

GESCHÄFTSMODELL Regeneron Pharmaceuticals develops, manufactures, and markets biopharmaceutical products – primarily monoclonal antibodies – and generates the majority of its revenues through product sales as well as collaboration income from partnerships, with the ophthalmology blockbuster Eylea and the immunology drug Dupixent serving as the central revenue drivers.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.